Smartlab Europe

Takeda’s Donation to Aid Earthquake Relief Efforts in Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Taiwan Launches $755M Pharma Resilience Plan to Boost Supply

Taiwan is preparing a four-year national pharmaceutical resilience preparedness...

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment...

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...
- Advertisement -

Takeda Pharmaceutical Company Limited announced 300 million Japanese yen donation to aid emergency relief for the earthquake on March 11, through The Japanese Red Cross Society, in view of the huge damages in the wide geographical area affected in prefectures such as Iwate, Miyagi, Fukushima and others. In addition to the cash donation aforementioned, Takeda is planning the donation of pharmaceutical products (both ethical and over-the-counter) and all other supports that are feasible for the Company.

We would like to express heartfelt condolences to the families of the victims, and we also sincerely wish the safety of the people affected by this earthquake and the earliest possible recovery of the relevant region.

Latest stories

Related stories

Taiwan Launches $755M Pharma Resilience Plan to Boost Supply

Taiwan is preparing a four-year national pharmaceutical resilience preparedness...

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment...

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »